The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of125I EGF to tumor plasma membrane preparations. Tumor with a B max ≥ 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R ≤ 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Benraad TJ, Foekens JA: Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem 27: 272–273, 1990
Bolla M, Chedin M, Souvignet C, Marron J, Arnould C, Chambaz EM: Estimation of epidermal growth factor receptor in 177 breast cancers. Correlation with prognostic factors. Breast Cancer Res Treat 16: 97–102, 1990
Bolla M, Chedin M, Colonna M, Marron J, Rostaing-Puissant B, Chambaz EM: Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur J Cancer 28A: 1052–1054, 1992
Falette N, Lefebvre ML, Meggouh F, Eynard M, Garin E, Saez S: Measurement of epidermal growth factor occupied and non occupied receptor sites in 216 human breast cancer biopsies. Breast Cancer Res Treat 20: 177–183, 1991
Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to oestrogen receptor and progestin receptor levels. Cancer Res 44: 3448–3453, 1984
Foekens JA, Portengen H, Van Putten WLJ, Trapman A, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insuline-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989
Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, François E, Milano G: Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Treat Res 17: 211–219, 1990
Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992
Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node positive breast cancer. Breast Cancer Res Treat 14: 77–90, 1989
Koenders PG, Beex LVAM, Geurts-Moespot A, Heuvel JJTM, Kienhuis CBM, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor positive human primary breast cancers. Cancer Res 51: 4544–4548, 1991
Koenders P, Beex LVAM, Kienhuis C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 23: abstract 16, 134, 1992
Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry Y, Farndon JR, Harris AL: Epidermal growth factor receptor: results of a six year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63: 146–151, 1991
Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10: 679–682, 1992
Rostaing-Puissant B, Chedin M, Chambaz EM, Bolla M: Activité protéine (Tyrosine)-kinases dans les tumeurs du sein. Relation avec les divers paramètres de pronostic. Bull Cancer 78: 482–483, 1991
Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL: Epidermal growth factor receptors and estrogen receptors in human breast cancer. Lancet i: 364–366, 1985
Sainsbury JRC, Farndon JR, Needham GK, Malcom AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet i: 1398–1402, 1987
Sokal R, Rohlt F (eds): Biometry. Freeman, New York, 1981
Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champene MH, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17: 83–90, 1990
Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27: 977–980, 1991
About this article
Cite this article
Bolla, M., Chedin, M., Colonna, M. et al. Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters. Breast Cancer Res Tr 29, 265–270 (1994). https://doi.org/10.1007/BF00666480
- epidermal growth factor receptor
- breast cancer
- prognostic factor